Winning combinations 

Since the launch of our first injector in 1996, close to four dozen combination products using devices designed and developed by SHL have been approved around the world. These winning combinations are delivered to patients by leading pharmaceutical brands in therapeutic areas such as multiple sclerosis, rheumatoid arthritis, migraine, type 2 diabetes and hypercholesterolemia, to name a few.

Owning over 20 years of experience in the medical device industry, SHL has grown into a global organization that boasts quite the formidable customer base. We work with the world’s leading biotechnology and pharmaceutical companies to develop advanced disposable and reusable drug delivery devices with fixed or variable dosing, high dose accuracy, and the ability to accommodate high volumes and high viscosities.

SHL has helped shape industry standards for the usability of autoinjectors with innovative designs and cutting-edge manufacturing processes. From bespoke projects to preconfigured devices, all our offerings are developed in close partnership with biopharmaceutical clients to ensure that their innovative, life-changing drugs are delivered to patients safely and efficiently. Scroll down to read about some of our most outstanding projects so far.

DAI®: Button activated autoinjector

2006 marked the commercial launch of one of the world’s first modern autoinjectors SHL’s Disposable Autoinjector, more commonly known as DAI®.

The first DAI® was built for a multinational biopharmaceutical company headquartered in the US. It is a button-activated, 3-step disposable device for 1 mL pre-filled syringes. We were tasked to design an injection device that could facilitate an easier subcutaneous self-injection experience compared to the alternative pre-filled syringe or vial. For this reason, DAI® features an ergonomic interface with two audible clicks at the beginning and end of injection, as well as an automatic delivery mechanism that successfully delivers the drug in a matter of seconds. As one of the first modern auto-injectors, DAI® helped set the standard for biological self-injection treatments worldwide.

The commercial launch of DAI® put SHL on the map as a recognized leader in the global autoinjector market. DAI® later went on to win the 2006 Taiwan Excellence Award for its innovative design features. And while the design of modern autoinjectors has since evolved, DAI® remains to be one of the most popular and sought-after autoinjectors today.

2006 marked the commercial launch of one of the world’s first modern autoinjectors  SHL’s Disposable Autoinjector, more commonly known as DAI®.

The first DAI® was built for a multinational biopharmaceutical company headquartered in the US. It is a button-activated, 3-step disposable device for 1 mL pre-filled syringes. We were tasked to design an injection device that could facilitate an easier subcutaneous self-injection experience compared to the alternative prefilled syringe or vial. For this reason, DAI® features an ergonomic interface with two audible clicks at the beginning and end of injection, as well as an automatic delivery mechanism that successfully delivers the drug in a matter of seconds. As one of the first modern autoinjectors, DAI® helped set the standard for biological self-injection treatments worldwide.

The commercial launch of DAI® put SHL on the map as a recognized leader in the global autoinjector market. DAI® later went on to win the 2006 Taiwan Excellence Award for its innovative design features. And while the design of modern autoinjectors has since evolved, DAI® remains to be one of the most popular and sought-after autoinjectors today.

PPI®: High-precision autoinjector for extremely viscous formulations

The development of the Precision Pen Injector (PPI®) is a story of uncompromising dedication to meeting industry challenges.

A Swedish company specializing in solutions for aesthetics and corrective treatment sought to introduce an autoinjector for its skin booster a highly viscous hyaluronic acid formulation of several hundred centipoise. The company needed a device that could deliver small and very precise doses of this treatment while addressing the challenges the filler market did not have at the time, such as drooling and overdosing.

To meet these challenges, our design engineers created the Rotaject®, a patented clock spring technology that made it possible for a mechanically driven injector to deliver small (10 μL) and consistent dosages of highly viscous formulations for up to 200 times from a 2.25 mL pre-filled syringe. Working with various study groups, we developed a user-friendly device that maintained a balance between its shape and weight versus its mechanical properties. The result was the PPI® a sleek and aesthetically pleasing pen injector that went on to win the prestigious Red Dot Design Award for product design in 2009.

The development of the Precision Pen Injector (PPI®) is a story of uncompromising dedication to meeting industry challenges.

A Swedish company specializing in solutions for aesthetics and corrective treatment sought to introduce an auto-injector for its skin booster a highly viscous hyaluronic acid formulation of several hundred centipoise. The company needed a device that could deliver small and very precise doses of this treatment while addressing the challenges the filler market did not have at the time, such as drooling and overdosing.

To meet these challenges, our design engineers created the Rotaject®, a patented clock spring technology that made it possible for a mechanically driven injector to deliver small (10 μL) and consistent dosages of highly viscous formulations for up to 200 times from a 2.25 mL pre-filled syringe. Working with various study groups, we developed a user-friendly device that maintained a balance between its shape and weight versus its mechanical properties. The result was the PPI® a sleek and aesthetically pleasing pen injector that went on to win the prestigious Red Dot Design Award for product design in 2009.

Previous
Next
Previous
Next

Molly®: SHL’s first preconfigured autoinjector

Molly® is SHL’s first preconfigured autoinjector designed to help pharmaceutical companies reduce initial investments and expedite development timelines.

Molly® features just two simple steps: uncap and inject. As a preconfigured autoinjector, it supports an array of patient groups with its intuitive features and compact design. It was developed with a range of spring options that can be adapted to suit a variety of drug characteristics; it is also designed with a power pack that utilizes a reduced number of components. Molly® is supported by SHL’s in-house tooling, assembly, testing, and final assembly capabilities to help customers save costs and speed up development. At the same time, the preconfigured program still offers customization flexibility that meets the requirements of various drug specifications and branding.

Introduced in 2010, the Molly® autoinjector is already commercialized in a wide range of shapes and colors within several therapeutic areas. Now, a second-generation is available for even higher volume production. To meet the growing request for stronger device technologies presented by the emergence of biologic and biosimilar drug preparations, the high-volume variation Molly® 2.25 is also available.

Molly® is SHL’s first preconfigured autoinjector designed to help pharmaceutical companies reduce initial investments and expedite development timelines.

Molly® features just two simple steps: uncap and inject. As a preconfigured autoinjector, it supports an array of patient groups with its intuitive features and compact design. It was developed with a range of spring options that can be adapted to suit a variety of drug characteristics; it is also designed with a power pack that utilizes a reduced number of components. Molly® is supported by SHL’s in-house tooling, assembly, testing, and final assembly capabilities to help customers save costs and speed up development. At the same time, the pre-configured program still offers customization flexibility that meets the requirements of various drug specifications and branding.

Introduced in 2010, the Molly® autoinjector is already commercialized in a wide range of shapes and colors within several therapeutic areas. Now, a second-generation is available for even higher volume production. To meet the growing request for stronger device technologies presented by the emergence of biologic and biosimilar drug preparations, the high-volume variation Molly® 2.25 is also available.